First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)

BACKGROUND: This phase 1 study evaluated PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in two clinical states of prostate cancer (PC), metastatic castration-resistant PC (mCRPC) and biochemical recurrence (BCR). METHODS: For dose escalation, patients with mCRPC received intramuscul...

Descripción completa

Detalles Bibliográficos
Autores principales: Autio, Karen A, Higano, Celestia S, Nordquist, Luke, Appleman, Leonard J, Zhang, Tian, Zhu, Xin-Hua, Babiker, Hani, Vogelzang, Nicholas J, Prasad, Sandip M, Schweizer, Michael T, Madan, Ravi A, Billotte, Stephane, Cavazos, Nora, Bogg, Orlaith, Li, Ray, Chan, Kam, Cho, Helen, Kaneda, Megan, Wang, I-Ming, Zheng, Jenny, Tang, Szu-Yu, Hollingsworth, Robert, Kern, Kenneth A, Petrylak, Daniel P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040068/
https://www.ncbi.nlm.nih.gov/pubmed/36948505
http://dx.doi.org/10.1136/jitc-2022-005702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040068/
https://www.ncbi.nlm.nih.gov/pubmed/36948505
http://dx.doi.org/10.1136/jitc-2022-005702

Ejemplares similares